A person with recurrent pericarditis knows the feeling. The pain subsides. Life starts to normalize. And then, weeks or months later, it comes back.
That cycle of recurrence is one of the most difficult aspects of the disease. Treatments that provide short-term relief matter.
Cardiol Therapeutics Inc.
749 posts
- From approximately six episodes per year to less than one. CEO David Elsley discusses the Phase II MAvERIC findings in recurrent pericarditis, and how those data helped form the basis for the now-enrolling pivotal Phase III MAVERIC trial. $CRDL
00:00 - Cardiol's President/CEO David Elsley sat down with Stocks to Watch to discuss our approach to targeting inflammation in heart disease — and what's ahead for $CRDL. 🎥 Watch the full interview: youtube.com/watch?v=NXkzgf… #HeartDisease #Biotech #CRDL #Pericarditis #Inflammation
- REPLAY: President/CEO David Elsley & CMO/Head of R&D Andrew Hamer joined @HCWCO yesterday in a Fireside Chat hosted by Brandon Folkes to discuss the pivotal Phase III MAVERIC trial, key value-driving milestones, and development of CRD-38. 🔗 Watch here: journey.ct.events/view/8d043006-…
- REMINDER: Cardiol Therapeutics will be presenting a Fireside Chat today at 1:30 p.m. ET at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the Nasdaq in New York City. $CRDL 📺Watch our Fireside Chat live via webcast — register here: journey.ct.events/view/8d043006-…
- We’re proud to support @PericarditisA 1st Annual Platypus Run on May 16, 2026! The event helps raise awareness of pericarditis and brings together patients, families, and supporters through a 5K run, 1-mile walk, and virtual participation option. We’re pleased to stand with TheThe Platypus Run is almost here! If you’re joining us in Albuquerque, we’ll see you Saturday, May 16 at 8:30am MDT. Participating virtually? You can complete your run or walk anytime during the week of May 16–23, wherever it works best for you! pericarditisalliance.org/events/
- Very informative paper from the great team of our MAVERIC trial collaborators at the @ClevelandClinic!Important article how to use multimodality imaging for pericarditis. Congratulations to our pericardial team
- Replying to @CardiolRxThese results support our ongoing Phase III MAVERIC trial, evaluating CardiolRx™ for the prevention of recurrent pericarditis. Enrollment has surpassed 75%, with full enrollment anticipated in the next few months. We’ll share the link to the full publication once it is
- Replying to @CardiolRxThe peer-reviewed findings demonstrate rapid and sustained reductions in pericarditis pain and inflammation, a substantial reduction in pericarditis episodes per year, and a favorable safety profile in patients with high baseline disease burden.
- Today we announced the results from our Phase II MAvERIC study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the Journal of the American Heart Association (@JAHA_AHA). #JAHA #ClinicalTrials #CardiolRx
- HFpEF now accounts for >50% of all heart failure cases — and most existing therapies were built for a different disease. It will affect nearly one in 10 people by the age of 45. In Canada, it is one of the leading causes of hospitalization for people over 65. The answer lies
- This week is Heart Failure Awareness Week in Canada. Over 850,000 Canadians are living with heart failure, with more than 100,000 new diagnoses expected this year. 1-in-4 people will develop HF in their lifetime. At Cardiol, we’re advancing anti-inflammatory and anti-fibrotic






